International Journal For Multidisciplinary Research

E-ISSN: 2582-2160   •   Impact Factor: 9.24

A Widely Indexed Open Access Peer Reviewed Multidisciplinary Bi-monthly Scholarly International Journal

Call for Paper Volume 7, Issue 3 (May-June 2025) Submit your research before last 3 days of June to publish your research paper in the issue of May-June.
Submit Research Paper Join as a Reviewer

Plagiarism is checked by the leading plagiarism checker TurnItIn

Call for Paper

Volume 7 Issue 3
May-June 2025

Submit your research paper

Indexing Partners
Academia Advanced Sciences Index Bielefeld Academic Search Engine CiteSeer DRJI Google Scholar Independent Search Engine & Directory Network ISI (International Scientific Indexing) Issuu Mendeley Research Networks
RefSeek ResearcherId - Thomson Reuters ResearchGate Scirus Scribd Semantic Scholar UTeM - Universiti Teknikal Malaysia Melaka Wiki for Call for Papers WorldCat Zenodo

Pharmacovigilance of Vonoprazan: a Review of Safety and Adverse Event Profiles

Author(s) Mr. Tejas Vinod Fendar, Mr. Dipak Vasant Pawar, Miss. Tejaswini Mahadev Ghorpade, Mr. Prem Dilip Fendar, Miss Gayatri Vilas Jadhao, Mr. Dhiraj D. Mangam, Dr. Avinash S. Jiddewar
Country India
Abstract Vonoprazan is a novel potassium-competitive acid blocker (P-CAB) used to treat acid-related disorders, including gastroesophageal reflux disease (GERD) and Helicobacter pylori eradication therapy. Compared to traditional proton pump inhibitors (PPIs), vonoprazan exhibits a faster onset of action and sustained acid suppression. This pharmacovigilance review evaluates its safety profile based on post-marketing surveillance and clinical studies.

Data from the Japanese Adverse Drug Event Report (JADER) database and systematic reviews indicate that vonoprazan has a generally comparable safety profile to PPIs. Common adverse events include diarrhea, liver function abnormalities, and rash. However, vonoprazan has been associated with an increased risk of hemorrhagic enterocolitis, necessitating further investigation. Unlike PPIs, it does not show a significant correlation with interstitial lung disease. Meta-analyses suggest no significant increase in overall adverse events compared to PPIs, with some studies reporting fewer gastrointestinal side effects.

Despite its favorable tolerability, long-term safety data remain limited. Continuous pharmacovigilance efforts and real-world studies are crucial to identifying rare but serious adverse effects. Future research should focus on elucidating the mechanisms underlying vonoprazan-associated risks and optimizing its safe clinical use.
Keywords Vonoprazan, Pharmacovigilance, Adverse Drug Reactions, Potassium-Competitive Acid Blocker, Proton Pump Inhibitors, Gastroesophagel Reflux Disease
Field Medical / Pharmacy
Published In Volume 7, Issue 3, May-June 2025
Published On 2025-05-30
DOI https://doi.org/10.36948/ijfmr.2025.v07i03.46234
Short DOI https://doi.org/g9mtrp
View / Download PDF File

Share this



E-ISSN 2582-2160
CrossRef

CrossRef DOI is assigned to each research paper published in our journal.

IJFMR DOI prefix is
10.36948/ijfmr

Downloads
Research Paper Format Copyright Permission Form and Undertaking Form Cover Page Vol 7 Isu 3Cover Page Vol 7 Isu 2Cover Page Vol 7 Isu 1

All research papers published on this website are licensed under Creative Commons Attribution-ShareAlike 4.0 International License, and all rights belong to their respective authors/researchers.

CC-BY-SA Open Access

About IJFMR
Fees & Payment
Current Issue
Publication Archive 		Submit Research Paper
Track Submission Status
Publication Guidelines
Publication Ethics
Peer Review & Plagiarism 		Join as a Reviewer
Editors & Reviewers
Reviewer Referral Program
Get Reviewer Membership Certi. 		Website/Journal Policies
Usage Policy
Content Policies
Privacy Policy
Contact Us +91-9687-828-838 editor@ijfmr.com